| Date Filed | Type | Description |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 07/17/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/06/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 05/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/23/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/17/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/08/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 05/05/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 04/28/2023 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 04/27/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/29/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Non-Disparagement. To the extent permitted by law, Executive understands and agrees that as a condition for payments and benefits under this Agreement, for a period of five years following the date hereof Executive shall not make any false, disparaging or derogatory statements to any person or entity, including any media outlet, regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company’ s business affairs and financial condition. Executive further agrees that as a condition for payments and benefits under this Agreement any statements made by Executive regarding the Company shall be consistent in tenor, tone and content with the statements made in the press release filed by the Company on or around the date hereof announcing Executiv...",
"Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics" |
|
|